UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

Clinical pharmacology and therapeutics, 2014-03, Vol.95 (3), p.294-306

2014

Volltextzugriff (PDF)

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

Leukemia, 2017-01, Vol.31 (1), p.75-82

2017

Volltextzugriff (PDF)

Response to ‘Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?’

Leukemia, 2017-03, Vol.31 (3), p.769-770

2017

Volltextzugriff (PDF)

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

Leukemia, 2013-05, Vol.27 (5), p.1201-1204

2013

Volltextzugriff (PDF)

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?%apos

Leukemia, 2017-03, Vol.31 (3), p.769

2017

Volltextzugriff (PDF)

TP53 loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137

Oncology reports, 2022-05, Vol.47 (5), p.1, Article 99

2022

Volltextzugriff (PDF)

Diagnostic Genomic Analysis is Prognostic in AYA ALL Patients Treated on a MRD-Stratified Pediatric Protocol

Blood Neoplasia, 2024-09, p.100041, Article 100041

2024

Volltextzugriff (PDF)

L’Esclavage de l’Africain en Amérique du 16e au 19e siècle : Les Héritages

2011

Volltextzugriff (PDF)

L’Esclavage de l’Africain en Amérique du 16e au 19e siècle

Presses universitaires de Perpignan, 2011

2011

Volltextzugriff (PDF)

Introduction

Presses universitaires de Perpignan, 2011

2011

Volltextzugriff (PDF)

Conclusion

Presses universitaires de Perpignan, 2011

2011

Volltextzugriff (PDF)

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines

PloS one, 2016-08, Vol.11 (8), p.e0161470

2016

Volltextzugriff (PDF)

RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)

PLoS genetics, 2022-10, Vol.18 (10), p.e1010300-e1010300

2022

Volltextzugriff (PDF)

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

PloS one, 2018-01, Vol.13 (1), p.e0192180

2018

Volltextzugriff (PDF)

The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism

Scientific reports, 2023-08, Vol.13 (1), p.13110-13110, Article 13110

2023

Volltextzugriff (PDF)

Fmr1 knockout mice show reduced anxiety and alterations in neurogenesis that are specific to the ventral dentate gyrus

Neurobiology of disease, 2009-11, Vol.36 (2), p.361-373

2009

Volltextzugriff (PDF)

KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease

Cancer letters, 2020-01, Vol.469, p.410-418

2020

Volltextzugriff (PDF)

Utilizing Remote Sensing and Data Analytics Techniques to Detect Methane Emissions from the Oil and Gas Industry and Assist with Sustainability Metrics

SPE production & operations, 2023-11, Vol.38 (4), p.640-650

2023

Volltextzugriff (PDF)

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Blood, 2024-08, Vol.144 (9), p.1022-1026

2024

Volltextzugriff (PDF)

Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia

Cancer letters, 2021-08, Vol.512, p.28-37

2021

Volltextzugriff (PDF)

HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort

Oncogene, 2022-02, Vol.41 (6), p.797-808

2022

Volltextzugriff (PDF)

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy

Leukemia, 2018-10, Vol.32 (10), p.2288-2291

2018

Volltextzugriff (PDF)

Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling

British journal of haematology, 2023-10, Vol.203 (2), p.282-287

2023

Volltextzugriff (PDF)

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro

Oncotarget, 2018-03, Vol.9 (17), p.13423-13437

2018

Volltextzugriff (PDF)

Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia

Cancer gene therapy, 2022-08, Vol.29 (8-9), p.1140-1152

2022

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(70)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(12)
Leukemia
(5)
Journal Of Food Science
(3)
Cancer Letters
(2)
Cancers
(2)
Genes
(2)
International Journal Of Speech Language Pathology
(2)
Journal Of Mammalogy
(2)
Leukemia & Lymphoma
(2)
Plos Genetics
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

Response to ‘Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?’

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?%apos

TP53 loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137

Diagnostic Genomic Analysis is Prognostic in AYA ALL Patients Treated on a MRD-Stratified Pediatric Protocol

L’Esclavage de l’Africain en Amérique du 16e au 19e siècle : Les Héritages

L’Esclavage de l’Africain en Amérique du 16e au 19e siècle

Introduction

Conclusion

ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines

RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)

ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells

The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism

Fmr1 knockout mice show reduced anxiety and alterations in neurogenesis that are specific to the ventral dentate gyrus

KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease

Utilizing Remote Sensing and Data Analytics Techniques to Detect Methane Emissions from the Oil and Gas Industry and Assist with Sustainability Metrics

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia

HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy

Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro

Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia

Suchergebnisse filtern